A Phase 2, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Vonoprazan 10 mg, 20 mg, and 40 mg Compared to Placebo for Relief of Episodic Heartburn in Subjects With Symptomatic Non-Erosive Gastroesophageal Reflux Disease
Latest Information Update: 28 Sep 2023
At a glance
- Drugs Vonoprazan (Primary)
- Indications Heartburn
- Focus Proof of concept; Therapeutic Use
- Acronyms PHALCON-NERD on-demand
- Sponsors Phathom Pharmaceuticals
- 26 Sep 2023 Results comparing the efficacy and safety of on-demand vonoprazan versus placebo in patients with NERD, published in the Alimentary Pharmacology and Therapeutics
- 08 Jan 2023 According to a Phathom Pharmaceuticals media release, results from this study were previously presented at the American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting.
- 23 Oct 2022 According to a Phathom Pharmaceuticals media release, Ronnie Fass, M.D., director of the Division of Gastroenterology and Hepatology and medical director of the Digestive Health Center at MetroHealth in Cleveland, Ohio, is a lead investigator of this trial.